Asset Details
Do you wish to reserve the book?
Essential updates 2017/2018: Recent topics in the treatment and research of gastric cancer in Japan
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Essential updates 2017/2018: Recent topics in the treatment and research of gastric cancer in Japan
Do you wish to request the book?
Essential updates 2017/2018: Recent topics in the treatment and research of gastric cancer in Japan
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Essential updates 2017/2018: Recent topics in the treatment and research of gastric cancer in Japan
2019
Overview
Recent developments in diagnostic technology, accumulated clinical effort and established evidence have boosted early detection and drastically improved early and long‐term outcomes of gastric cancer. However, gastric cancer continues to be one of the most aggressive and life‐threatening malignancies among all cancers and is a global health problem. Between January 2017 and December 2018, various fascinating reports of managements and research were published, including the new 15th Japanese Classification of Gastric Carcinoma reflecting the 8th American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) tumor, node and metastasis (TNM) classification (October 2017) and the new Gastric Cancer Treatment Guidelines version 5 (January 2018). Moreover, pivotal molecular features of gastric cancer were clarified by the worldwide cancer genome project, and various treatment targets and biomarkers such as circulating DNAs and microRNAs were detected. Novel treatment options using programmed cell death protein 1 immune checkpoint inhibitors have been started. In this review, we summarize the recent topics of classification, guidelines, and clinical and basic research in order to bring new insights to gastric cancer treatment. The greatest change in the 15th edition of JGCA staging systems for gastric cancer was the separate inclusion of N3a and N3b. In the new 15th JGCA classification, T1–T3 disease was upstaged with N3b, T4aN3a was downstaged from IIIC to IIIB and T4bN0 and T4aN2 were downstaged from IIIB to IIIA.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
